Navigation Links
Thoratec Reports 44 Percent Increase in Third Quarter Revenues
Date:10/30/2008

, the effects of FDA regulatory requirements, the effects of healthcare reimbursement and coverage policies, the effects of seasonality in Thoratec product sales, the effects of price competition from any Thoratec competitors and the effects of any merger and acquisition related activities. Forward-looking statements contained in this press release should be considered in light of these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K, and as may be updated in subsequent SEC filings. Thee forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Thoratec Schedules Third Quarter 2008 Conference Call, Webcast
2. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
3. Thoratec Presentation at JP Morgan Conference to be Webcast
4. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
5. Thoratec Presentation at Bear Stearns Conference To Be Webcast
6. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
7. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
8. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
9. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
10. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
11. United Therapeutics Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:12/25/2014)... The report “Service Quality Management and ... Provider Type - Global Advancements, Worldwide Forecasts & Analysis ... analysis and forecasting of revenues. , Browse 152 ... and in-depth TOC on “Service Quality Management (SQM) and ...
(Date:12/24/2014)... Solutions , Inc. (NASDAQ: BLFS ), a leading ... storage and cryopreservation freeze media and ... or the "Company"), today announced that it will hold its ... "Annual Meeting"). Because the expected date for the ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... Oct. 9 A homegrown New Jersey company ... pedigree of pharmaceuticals everywhere. Secure Symbology, (http://www.securesymbology.com ), ... as an,Honored Finalist as Emerging Business of the ... for its vision to wipe out counterfeit drugs,worldwide. ...
... Inc.,(Nasdaq: ORCH ), a leading worldwide provider ... of James F. Smith as Vice,President and Chief ... A. Bologna, Orchid Cellmark,s President and Chief Executive ... Orchid Cellmark more than 25 years of,extensive domestic ...
... 9 Tandem Labs, a leading contract,research ... (PD) services to the pharmaceutical,industry, announced that ... 5000(TM),and 4000(TM) LC/MS/MS systems for its New ... the facility,s current triple,quadrupole LC/MS/MS capacity, allowing ...
Cached Biology Technology:Secure Symbology: Making New Jersey Proud While Saving Lives 2Orchid Cellmark Appoints James F. Smith Chief Financial Officer 2Orchid Cellmark Appoints James F. Smith Chief Financial Officer 3Tandem Labs' New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England 2
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ...
(Date:12/15/2014)... 12, 2014 Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... Facial Recognition Market 2015-2019" report to their offering. ... Facial recognition is a technology used for the identification ... feature of a person such as nose, jaw edges, ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... international effort to assess the status of dozens of European ... northeast Atlantic are being fished sustainably today and that, given ... in the Cell Press journal Current Biology on ... that the European Union,s Common Fisheries Policy is failing, the ...
... the time, it takes decades of accumulating genetic errors for ... of cancer in adults, it leaves a gap in understanding ... published in the July issue of the Proceedings of ... piece of the pediatric cancer puzzle. Changxian Shen, PhD, senior ...
... (July 19, 2013) Researchers at the University of ... gene associated with human autoimmune disease. The ... set into motion new treatment approaches for autoimmune diseases ... key to these advances may lie with a better ...
Cached Biology News:European fish stocks poised for recovery 2Study finds missing piece of pediatric cancer puzzle 2U of M researchers identify new functions for autoimmune disease 'risk' gene 2
...
... Drummond Scientific has a long ... of microinjection apparatus. Several years ago ... positive displacement microdispenser was being modified ... this unit by redesigning the microdispenser ...
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
... Smart Minis 150V power supply (Cat. No. ... supplies designed to meet most electrophoresis needs ... unit. The Minis 150V power supply is ... Power Supply is designed for individuals to ...
Biology Products: